ReviewAmerican journal of translational research2018
Gankyrin as a potential target for tumor therapy: evidence and perspectives.
Review in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Gankyrin-Protein Interactions in GI Cancers: A Novel Target of New Therapeutics.Chronic diseases and translational medicine · 2025Review
- Epstein-Barr virus nuclear antigen 1 upregulatesGenes & cancer · 2025Article
- Structural modification of the propyl linker of cjoc42 in combination with sulfonate ester and triazole replacements for enhanced gankyrin binding and anti-proliferative activity.Bioorganic & medicinal chemistry · 2024Article
- Synthesis and evaluation of 2,5-substituted pyrimidines as small-molecule gankyrin binders.Future medicinal chemistry · 2024Article
- A New Insight Into p53-Inhibiting Genes in Epstein–Barr Virus-Associated Gastric AdenocarcinomaIranian biomedical journal · 2023Article
- Assembly checkpoint of the proteasome regulatory particle is activated by coordinated actions of proteasomal ATPase chaperones.Cell reports · 2022Article
- Identification of Tumor-SuppressiveInternational journal of molecular sciences · 2022Article
- Article
- Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin.Frontiers in pharmacology · 2021Article
- Increased Expression of Gankyrin and Stemness Factor Oct-4 are Associated with Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients.Pathology oncology research : POR · 2020Article
- LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells.OncoTargets and therapy · 2020Article
- Role of a 19S Proteasome Subunit- PSMD10International journal of stem cells · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gankyrin (also known as PSMD10 or p28GANK), engages in diverse biological processes, including cellular growth, proliferation and invasion. Several studies have demonstrated that Gankyrin is a candidate oncogene. In parallel, the dysregulation of Gankyrin has been observered in a variety of human cancer. Overexpression of Gankyrin is involved in tumor initiation and progression by regulating several signaling pathways that control cell-cycle process, cell growth, apoptosis, et al. On the contrary, downregulation of Gankyrin significantly inhibits cell growth, proliferation and metastasis. Therefore, Gankyrin appears to be a potential target for tumor therapy. Herein, this review summarizes the current knowledge in understanding the biological functions and oncogenic role of Gankyrin in human cancers from the perspective of clinical-pathological significances, aiming to provide guidance for the development of Gankyrin-targeted therapy.
Indexed as
Identifiers
30093934PMC6079124W2989008418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.